NBIX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
959.0M
+17.7%
814.5M
+1.1%
805.5M
+1.3%
794.9M
+15.6%
687.5M
Cost of Revenue
23.2M
+68.1%
13.8M
-21.6%
17.6M
+25.7%
14.0M
+35.9%
10.3M
Gross Profit
935.8M
+16.9%
800.7M
+1.6%
787.9M
+0.9%
780.9M
+15.3%
677.2M
Operating Expenses
784.3M
+23.3%
635.9M
+10.2%
577.0M
+6.5%
541.9M
+1.9%
531.6M
R&D
326.7M
+10.3%
296.2M
+14.7%
258.2M
+3.3%
250.0M
+2.3%
244.3M
SG&A
439.7M
+38.1%
318.5M
+5.5%
301.8M
+3.5%
291.6M
+1.9%
286.3M
Operating Income
151.5M
-8.1%
164.8M
-21.9%
210.9M
-11.8%
239.0M
+64.1%
145.6M
EBITDA
161.3M
-16.6%
193.3M
-17.9%
235.4M
-4.7%
247.0M
+63.7%
150.9M
Net Income
144.4M
-27.0%
197.9M
+28.8%
153.7M
-26.6%
209.5M
+94.9%
107.5M
EPS (Basic)
$1.43
-27.4%
$1.97
+27.9%
$1.54
-27.0%
$2.11
+93.6%
$1.09
EPS (Diluted)
$1.39
-27.2%
$1.91
+29.1%
$1.48
-27.5%
$2.04
+92.5%
$1.06
Shares (Diluted)
104.2M
+0.8%
103.4M
-0.6%
104.0M
+1.5%
102.5M
+1.5%
101.0M
Neurocrine Biosciences (NBIX) โ€” Financials